MCID: PSD088
MIFTS: 39

Pseudobulbar Affect

Categories: Mental diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Pseudobulbar Affect

MalaCards integrated aliases for Pseudobulbar Affect:

Name: Pseudobulbar Affect 54
Emotional Lability 54 30 6
Involuntary Emotional Expression Disorder 54 74
Pathological Crying and Laughing 54
Emotional Incontinence 54
Mood Swings 74
Pba 54

Classifications:



External Ids:

Summaries for Pseudobulbar Affect

NIH Rare Diseases : 54 Pseudobulbar affect (PBA) is a condition characterized by episodes of sudden, uncontrollable and inappropriate episodes of crying or laughing. The condition can be embarrassing and disruptive to daily life. It typically occurs in people with certain neurological conditions or injuries that affect the way the brain controls emotion. It is common in stroke survivors and people with conditions such as dementia, multiple sclerosis, Lou Gehrig�??s disease (ALS) and traumatic brain injury. PBA is thought to affect more than one million people in the United States. The goal of treatment is to reduce the severity and frequency of emotional outbursts. Treatment may include the use of antidepressants and/or a combination of dextromethorphan and quinidine.

MalaCards based summary : Pseudobulbar Affect, also known as emotional lability, is related to kuru and colloid cysts of third ventricle, and has symptoms including mental and behavioral signs and symptoms, nervousness and demoralization and apathy. An important gene associated with Pseudobulbar Affect is CYP2D6 (Cytochrome P450 Family 2 Subfamily D Member 6). The drugs Acetylcholine and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include brain, bone and spinal cord.

Wikipedia : 77 Pseudobulbar affect (PBA), or emotional incontinence, is a type of emotional disturbance characterized... more...

Related Diseases for Pseudobulbar Affect

Diseases related to Pseudobulbar Affect via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 55)
# Related Disease Score Top Affiliating Genes
1 kuru 11.2
2 colloid cysts of third ventricle 11.2
3 childhood-onset cerebral x-linked adrenoleukodystrophy 11.2
4 progressive bulbar palsy 11.2
5 chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids 11.0
6 multiple sclerosis 10.4
7 attention deficit-hyperactivity disorder 10.4
8 pol iii-related leukodystrophies 10.4
9 brain injury 10.3
10 traumatic brain injury 10.3
11 dementia 10.3
12 huntington disease 10.3
13 motor neuron disease 10.1
14 amyotrophic lateral sclerosis 1 10.1
15 intermittent claudication 10.1
16 lateral sclerosis 10.1
17 depression 10.1
18 oppositional defiant disorder 10.0
19 blood group, colton system 10.0
20 hepatitis c virus 10.0
21 alport syndrome 10.0
22 hepatitis 10.0
23 x-linked alport syndrome 10.0
24 hepatitis c 10.0
25 pain - chronic 10.0
26 isolated optic neuritis 10.0
27 alzheimer disease 9.9
28 breast cancer 9.9
29 parkinson disease, late-onset 9.9
30 nance-horan syndrome 9.9
31 stroke, ischemic 9.9
32 meningioma, familial 9.9
33 major depressive disorder 9.9
34 spinal meningioma 9.9
35 mental depression 9.9
36 epilepsy 9.9
37 skull base meningioma 9.9
38 secretory meningioma 9.9
39 movement disease 9.9
40 acute disseminated encephalomyelitis 9.9
41 cerebellar degeneration 9.9
42 paraneoplastic cerebellar degeneration 9.9
43 systemic lupus erythematosus 9.9
44 autism 9.9
45 autism spectrum disorder 9.9
46 borderline personality disorder 9.9
47 personality disorder 9.9
48 lupus erythematosus 9.9
49 encephalopathy 9.9
50 dementia pugilistica 9.9

Graphical network of the top 20 diseases related to Pseudobulbar Affect:



Diseases related to Pseudobulbar Affect

Symptoms & Phenotypes for Pseudobulbar Affect

UMLS symptoms related to Pseudobulbar Affect:


mental and behavioral signs and symptoms, nervousness, demoralization and apathy, other signs and symptoms involving emotional state, signs and symptoms involving emotional state, pregnancy mood swing

Drugs & Therapeutics for Pseudobulbar Affect

Drugs for Pseudobulbar Affect (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 539)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
2
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 62-31-7, 51-61-6 681
3
Lorazepam Approved Phase 4 846-49-1 3958
4
Atropine Approved, Vet_approved Phase 4 5908-99-6, 51-55-8 174174
5
Biperiden Approved, Investigational Phase 4 514-65-8 2381
6
Droperidol Approved, Vet_approved Phase 4 548-73-2 3168
7
Diazepam Approved, Illicit, Investigational, Vet_approved Phase 4 439-14-5 3016
8
Midazolam Approved, Illicit Phase 4,Not Applicable 59467-70-8 4192
9
Naltrexone Approved, Investigational, Vet_approved Phase 4,Early Phase 1 16590-41-3 5360515
10
Ethanol Approved Phase 4,Phase 1,Phase 2,Not Applicable,Early Phase 1 64-17-5 702
11
Valproic Acid Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 99-66-1 3121
12
Risperidone Approved, Investigational Phase 4,Phase 3,Not Applicable 106266-06-2 5073
13
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 2,Not Applicable 50-28-2 5757
14
Polyestradiol phosphate Approved Phase 4,Phase 2,Not Applicable 28014-46-2
15
Citalopram Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 59729-33-8 2771
16
Guanfacine Approved, Investigational Phase 4,Phase 1,Phase 2,Not Applicable 29110-47-2 3519
17
Quinidine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 56-54-2 441074
18
Dextromethorphan Approved Phase 4,Phase 3,Phase 2,Phase 1 125-71-3 5362449 5360696
19
Guaifenesin Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 93-14-1 3516
20
Prednisone Approved, Vet_approved Phase 4,Phase 1 53-03-2 5865
21
Norepinephrine Approved Phase 4 51-41-2 439260
22
Levomilnacipran Approved, Investigational Phase 4 96847-54-0
23
Milnacipran Approved, Investigational Phase 4 92623-85-3 65833
24
Leuprolide Approved, Investigational Phase 4 53714-56-0 657181 3911
25
Acetylcysteine Approved, Investigational Phase 4,Phase 2 616-91-1 12035
26
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
27
Lamotrigine Approved, Investigational Phase 4,Phase 3 84057-84-1 3878
28
Ziprasidone Approved Phase 4 146939-27-7 60854
29
Ketamine Approved, Vet_approved Phase 4,Phase 1,Phase 2,Not Applicable 6740-88-1 3821
30
Methamphetamine Approved, Illicit Phase 4,Phase 1 537-46-2 10836
31
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 1177-87-3
32
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-02-2 5743
33
Oseltamivir Approved Phase 4 204255-11-8, 196618-13-0 65028
34
Pramipexole Approved, Investigational Phase 4,Phase 3,Phase 1 104632-26-0 119570 59868
35
Progesterone Approved, Vet_approved Phase 4 57-83-0 5994
36
Oxytocin Approved, Vet_approved Phase 4,Not Applicable,Early Phase 1 50-56-6 53477758 439302
37
Paroxetine Approved, Investigational Phase 4,Phase 3 61869-08-7 43815
38
Bupropion Approved Phase 4 34841-39-9, 34911-55-2 444
39
Fluoxetine Approved, Vet_approved Phase 4,Phase 3,Phase 2 54910-89-3 3386
40
Sertraline Approved Phase 4 79617-96-2 68617
41
Rivastigmine Approved, Investigational Phase 4,Phase 1 123441-03-2 77991
42
Olanzapine Approved, Investigational Phase 4,Phase 3,Phase 2 132539-06-1 4585
43 Nutmeg Approved Phase 4
44
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3 83-43-2 6741
45
Histamine Approved, Investigational Phase 4 51-45-6 774
46
Promethazine Approved, Investigational Phase 4,Phase 1 60-87-7 4927
47
Methotrexate Approved Phase 4,Phase 3,Phase 2 1959-05-2, 59-05-2 126941
48
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3 302-25-0
49
rituximab Approved Phase 4,Phase 3 174722-31-7 10201696
50
Acetaminophen Approved Phase 4 103-90-2 1983

Interventional clinical trials:

(show top 50) (show all 666)
# Name Status NCT ID Phase Drugs
1 Efficacy Study of Botox for Depression Unknown status NCT01556971 Phase 4 Botox;Saline Solution
2 Optimization of Procedural Sedation Protocol Used for Dental Care Delivery in People With Mental Disability Unknown status NCT02078336 Phase 4 Midazolam Mylan;Lorazepam Mylan;Valium + Akineton + Dehydrobenzperidol + Atropine sulfate
3 Management of Chronic Pain in Military Patients With Injuries Sustained During Active Duty Unknown status NCT01616342 Phase 4
4 Low Dose Naltrexone for Treatment of Pain in Patients With Fibromyalgia - Effect Via a Central Mechanism? Unknown status NCT02806440 Phase 4 Low dose naltrexone;Placebo
5 Safety, Tolerability and Effectiveness of Nuedexta in the Treatment of Pseudobulbar Affect (PBA) Completed NCT01799941 Phase 4 Nuedexta (DM 20 mg/Q 10 mg)
6 Steroid-induced Mood Changes in Patients With Inflammatory Bowel Disease Completed NCT01981889 Phase 4 Prednisone
7 Depakote (Divalproex Sodium) for Children With Temper Dysregulation and Severe Mood Swings Completed NCT02078596 Phase 4 Divalproex
8 An Efficacy, Safety And Tolerability Study of Flexibly Dosed Paliperidone Extended-Release (ER) in Participants With Schizophrenia Completed NCT00757705 Phase 4 Paliperidone ER
9 Paliperidone Extended Release in Schizophrenia Participants With Duration of Illness Less Than 10 Years Completed NCT01362439 Phase 4 Paliperidone ER
10 Milnacipran for Chronic Pain in Knee Osteoarthritis Completed NCT01510457 Phase 4 Milnacipran;Placebo
11 A Study to Evaluate Flexible Dose of Paliperidone Extended Release (ER) and Clinical Response in Participants With Schizophrenia Completed NCT01577160 Phase 4 Paliperidone ER
12 Switching From Oral Antipsychotics to Long-Acting Risperidone in Participants With Schizophrenia Completed NCT01726335 Phase 4 Risperidone prolonged release
13 Safety and Efficacy Study of Paliperidone Extended Release (ER) Among Thai Schizophrenia Participants Completed NCT01387542 Phase 4 Paliperidone extended release (ER)
14 PaliperidoNe Extended-Release [ER] Dosing and Clinical Response in Acute Schizophrenia Completed NCT00761189 Phase 4 Paliperidone
15 Paliperidone Extended Release(ER) Effectiveness Study to Evaluate the Objective Symptom Change and Symptomatic Remission Completed NCT00761579 Phase 4 Paliperidone
16 An Efficacy and Safety Study of Risperidone Long-Acting Microspheres in Participants With Schizophrenia, Schizophreniform or Schizoaffective Disorders Completed NCT01855074 Phase 4 Risperidone
17 Efficacy Study of Paliperidone to Evaluate Subjective Change in Well-being and Drug Attitude in Schizophrenic Participants Completed NCT00784238 Phase 4 Paliperidone
18 A Phase 4 Study to Evaluate Response to Treatment and Safety of Paliperidone Extended-Release in Participants With Schizophrenia Completed NCT00915512 Phase 4 Paliperidone extended-release (ER)
19 A Study to Evaluate Participants Satisfaction, Quality of Life and Effectiveness of Flexible-Dose of Paliperidone Extended Release (ER) in Participants With Schizophrenia, Previously Treated With Risperidone Completed NCT01010776 Phase 4 Paliperidone Extended Release (ER)
20 An Efficacy and Safety Study of Long-Term Risperidone Microspheres in Participants With Schizophrenia Completed NCT00269919 Phase 4 Risperidone Long-Acting Injectable (RLAI)
21 An Efficacy and Safety Study of Long Acting Injectable Risperidone and Oral Risperidone in Participants With Schizophrenia or Schizoaffective Disorder Completed NCT00992407 Phase 4 Risperidone long acting injectables;Risperidone tablets
22 A Follow-Up Study of Schizophrenic Participants Following Treatment Discontinuation After Remission From a First Psychotic Episode Completed NCT00378092 Phase 4 Oral risperidone;Risperidone Long-Acting Injection (RLAI);Risperidone Long-Acting Injection (RLAI)
23 An Efficacy and Safety Study of Long-acting Risperidone in Participants With Schizophrenia or Schizoaffective Disorders Who Are Receiving Psychiatric Home Care Treatment Completed NCT00526877 Phase 4 Risperidone
24 Substudy on the Mechanistic Plausibility of the Clinical Benefits of Adaptive Servo-ventilation Completed NCT01164592 Phase 4
25 Effective Measurement of Risperidone Treatment Outcome for Persons With Borderline Personality Disorder Completed NCT00204347 Phase 4 risperidone
26 Impact of Hot Flashes on Sleep and Mood Disturbance Completed NCT01116401 Phase 4 leuprolide
27 Open-Label Study of N-Acetylcysteine in Children and Adolescents 5-17 With Bipolar Spectrum Disorders Completed NCT02357290 Phase 4 Open-label Treatment with N-Acetylcysteine
28 Pioglitazone in Patients With Mood Disorders Completed NCT01559857 Phase 4 Pioglitazone;Sugar Pill
29 Clinical Trial of Lamotrigine to Reverse Cognitive Impairment in Chronic Corticosteroid-Treated Patients Completed NCT00223262 Phase 4 Lamotrigine (Drug)
30 Network Connectivity and Inhibitory Control Under Atomoxetin Challenge- A Pharmacological 'Resting State' and 'Inhibiton Task' Study in Patients With ADHD Completed NCT03661788 Phase 4 Atomoxetine;Placebos
31 An Investigation of Sleep Architecture in Ziprasidone-Treated Bipolar Depression Completed NCT00835107 Phase 4 ziprasidone hydrochloride;placebo
32 Ketamine as an Anaesthetic Agent in Electroconvulsive Therapy (ECT) Completed NCT00680433 Phase 4 Ketamine;Saline
33 Creatine as a Treatment Option for Depression in Methamphetamine Using Females Completed NCT01514630 Phase 4 Creatine monohydrate
34 Dexamethasone and Ketamine on Change of Postoperative Mood Completed NCT03194594 Phase 4 Ketamine Hydrochloride, dexamethasone, and combination of two drugs
35 Symptomatic Remission and Social Function in Participants Treated With Paliperidone Extended Release (ER) Completed NCT01577186 Phase 4 Paliperidone ER
36 Anterior Pituitary Hormone Replacement in Traumatic Brain Injury Completed NCT00957671 Phase 4 Recombinant human growth hormone
37 Platelet Rich Plasma (PRP) in Total Knee Replacement Completed NCT00826098 Phase 4
38 Intra-nasal Ketamine for Analgesia in the Emergency Department Completed NCT01686009 Phase 4 Intra-nasal ketamine
39 Effect of Oseltamivir on Cognitive Function in Subjects With Influenza Completed NCT01249833 Phase 4 Oseltamivir
40 Imaging Dopamine Release in Depression Completed NCT02033369 Phase 4 Pramipexole
41 Perimenopausal Effects of Estradiol on Reward Responsiveness Completed NCT02255175 Phase 4 Estradiol;Progesterone
42 Oxytocin and Attachment-related Interpretation Bias Completed NCT02737254 Phase 4 Oxytocin;Placebo
43 Predictors of Antidepressant Response Completed NCT02178696 Phase 4 Celexa or other antidepressant as clinically indicated
44 Study of the Effects of Current Drug Treatments on Levels of Certain Brain Chemicals in Alzheimer's Disease Completed NCT00104442 Phase 4 Rivastigmine
45 Ontario Multidetector Computed Tomographic (MDCT) Coronary Angiography Study (OMCAS) Completed NCT00371891 Phase 4
46 Evaluating the Effectiveness of Sertraline in Treating Women With Premenstrual Dysphoric Disorder Completed NCT00536198 Phase 4 Sertraline;Placebo
47 A Trial Comparing Risperidone Long-Acting Injection With Oral Antipsychotic in the Treatment of Early Psychosis Completed NCT00246259 Phase 4 Risperidone long-acting injection (LAI);Oral Antipsychotic
48 A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors Completed NCT02019264 Phase 4 APD356-Lorcaserin hydrochloride;Placebo
49 A Study on The Safety of Administering Rituximab at A More Rapid Rate in Patients With Rheumatoid Arthritis Completed NCT01382940 Phase 4 rituximab;methotrexate;methylprednisolone;acetaminophen;antihistamine
50 A Study of Tocilizumab in Comparison to Etanercept in Participants With Rheumatoid Arthritis and Cardiovascular Disease Risk Factors Completed NCT01331837 Phase 4 Etanercept;Tocilizumab

Search NIH Clinical Center for Pseudobulbar Affect

Genetic Tests for Pseudobulbar Affect

Genetic tests related to Pseudobulbar Affect:

# Genetic test Affiliating Genes
1 Emotional Lability 30

Anatomical Context for Pseudobulbar Affect

MalaCards organs/tissues related to Pseudobulbar Affect:

42
Brain, Bone, Spinal Cord, Prostate, Testes, Kidney, Ovary

Publications for Pseudobulbar Affect

Articles related to Pseudobulbar Affect:

(show top 50) (show all 148)
# Title Authors Year
1
Genome-wide analysis of emotional lability in adult attention deficit hyperactivity disorder (ADHD). ( 31085060 )
2019
2
Assessment of Use of Combined Dextromethorphan and Quinidine in Patients With Dementia or Parkinson Disease After US Food and Drug Administration Approval for Pseudobulbar Affect. ( 30615021 )
2019
3
Is Emotional Lability Distinct From "Angry/Irritable Mood," "Negative Affect," or Other Subdimensions of Oppositional Defiant Disorder in Children With ADHD? ( 26842831 )
2019
4
Pseudobulbar Affect in Parkinsonian Disorders: A Review. ( 30732430 )
2019
5
The effects of emotional lability, mind wandering and sleep quality on ADHD symptom severity in adults with ADHD. ( 30384113 )
2019
6
Pharmacotherapy for the pseudobulbar affect in individuals who have sustained a traumatic brain injury: a systematic review protocol. ( 30204664 )
2018
7
Safety, Tolerability, and Effectiveness of Dextromethorphan/Quinidine for Pseudobulbar Affect Among Study Participants With Traumatic Brain Injury: Results From the PRISM-II Open Label Study. ( 29477412 )
2018
8
Emotional Lability as a Unique Presenting Sign of Suspected Chronic Traumatic Encephalopathy. ( 29568656 )
2018
9
Pseudobulbar Affect Due to Skull Base Meningioma Resolving After Temporal Lobectomy for Epilepsy. ( 29747704 )
2018
10
Pseudobulbar affect as a negative prognostic indicator in amyotrophic lateral sclerosis. ( 29527672 )
2018
11
Pseudobulbar Affect Correlates With Mood Symptoms in Parkinsonian Disorders but Not Amyotrophic Lateral Sclerosis. ( 29505320 )
2018
12
A Major Depressive Disorder in a Patient with Pseudobulbar Affect. ( 30820367 )
2018
13
Pseudobulbar affect: Prevalence and association with symptoms in multiple sclerosis. ( 30588376 )
2018
14
Identification of pseudobulbar affect symptoms in the nursing home setting: Development and assessment of a screening tool. ( 28807457 )
2018
15
Revisiting the pathoanatomy of pseudobulbar affect: mechanisms beyond corticobulbar dysfunction. ( 29092641 )
2018
16
Correlation between cognitive impairment during the acute phase of first cerebral infarction and development of long-term pseudobulbar affect. ( 29636612 )
2018
17
Pseudobulbar Affect in Survivors of Extreme Prematurity With Cerebellar Injury: Support for the Cerebellar Link in Pathologic Laughter and Crying. ( 29961526 )
2018
18
Dextromethorphan/Quinidine for Pseudobulbar Affect Following Stroke: Safety and Effectiveness in the PRISM II Trial. ( 29964212 )
2018
19
Pseudobulbar affect after stroke: a narrative review. ( 30213256 )
2018
20
Emotional Lability in Preschoolers With Symptoms of ADHD. ( 25804545 )
2018
21
The Impact of Emotional Lability Symptoms During Childhood in Adults With ADHD. ( 28760090 )
2018
22
A daily diary study of posttraumatic stress, experiential avoidance, and emotional lability among inpatient nurses. ( 28816380 )
2018
23
Emotional lability and affective synchrony in posttraumatic stress disorder pathology. ( 29197703 )
2018
24
Measuring child and adolescent emotional lability: How do questionnaire-based ratings relate to experienced and observed emotion in everyday life and experimental settings? ( 29845690 )
2018
25
The Relationship Between Neuropsychological Deficits and Emotional Lability in Adults With ADHD. ( 29890879 )
2018
26
Keeping Emotions in Mind: The Influence of Working Memory Capacity on Parent-Reported Symptoms of Emotional Lability in a Sample of Children With and Without ADHD. ( 30333774 )
2018
27
The Neural Correlates of Emotional Lability in Children with Autism Spectrum Disorder. ( 28506079 )
2017
28
Anti-Yo Mediated Paraneoplastic Cerebellar Degeneration Associated with Pseudobulbar Affect in a Patient with Breast Cancer. ( 28377827 )
2017
29
The Characteristics and Age Effects of Emotional Lability in ADHD Children With and Without Oppositional Defiant Disorder. ( 29224418 )
2017
30
Use of Compounded Dextromethorphan-Quinidine Suspension for Pseudobulbar Affect in Hospice Patients. ( 27997281 )
2017
31
Pseudobulbar Affect: What Nurses, Stroke Survivors, and Caregivers Need to Know. ( 28125430 )
2017
32
Treatment of Pseudobulbar Affect With Fluoxetine and Dextromethorphan in a Woman With Multiple Sclerosis. ( 28691510 )
2017
33
Introduction to pseudobulbar affect: setting the stage for recognition and familiarity with this challenging disorder. ( 29297656 )
2017
34
Pharmacotherapeutic management of pseudobulbar affect. ( 29297657 )
2017
35
ADHD Symptom Rebound and Emotional Lability With Lisdexamfetamine Dimesylate in Children Aged 6 to 12 Years. ( 23407278 )
2017
36
Childhood Maltreatment, Emotional Lability, and Alcohol Problems in Young Adults At-Risk for ADHD: Testing Moderation and Moderated Moderation. ( 28557570 )
2017
37
Effects of stimulants and atomoxetine on emotional lability in adults: A systematic review and meta-analysis. ( 28646732 )
2017
38
Methylation of the glucocorticoid receptor gene, nuclear receptor subfamily 3, group C, member 1 (NR3C1), in maltreated and nonmaltreated children: Associations with behavioral undercontrol, emotional lability/negativity, and externalizing and internalizing symptoms. ( 29162187 )
2017
39
Cortisol awakening response in adults with attention deficit hyperactivity disorder: Subtype differences and association with the emotional lability. ( 27084305 )
2016
40
Emotional lability and affective synchrony in borderline personality disorder. ( 27362623 )
2016
41
An open-label study to assess safety, tolerability, and effectiveness of dextromethorphan/quinidine for pseudobulbar affect in dementia: PRISM II results. ( 26471212 )
2016
42
Association of Pseudobulbar Affect symptoms with quality of life and healthcare costs in Veterans with traumatic brain injury. ( 26519634 )
2016
43
Prevalence of pseudobulbar affect symptoms and clinical correlates in nursing home residents. ( 26526856 )
2016
44
Pseudobulbar affect (PBA) in an incident ALS cohort: results from the Apulia registry (SLAP). ( 26588919 )
2016
45
Prevalence of Pseudobulbar Affect following Stroke: A Systematic Review and Meta-Analysis. ( 26776437 )
2016
46
Pseudobulbar Affect or Depression in Dementia? ( 26899823 )
2016
47
Behavioral Treatment of Pseudobulbar Affect: A Case Report. ( 27091117 )
2016
48
PRISM II: an open-label study to assess effectiveness of dextromethorphan/quinidine for pseudobulbar affect in patients with dementia, stroke or traumatic brain injury. ( 27276999 )
2016
49
Cough Suppressant and Fluoxetine in the Treatment of Pseudobulbar Affect: A Case Report. ( 27496344 )
2016
50
Erratum to: PRISM II: an open-label study to assess effectiveness of dextromethorphan/quinidine for pseudobulbar affect in patients with dementia, stroke or traumatic brain injury. ( 27590297 )
2016

Variations for Pseudobulbar Affect

ClinVar genetic disease variations for Pseudobulbar Affect:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 46;XY;t(9;11)(q34;p11.2)dn Translocation Pathogenic
2 46;XX;t(2;11)(q11.2;p13)dn Translocation Pathogenic

Expression for Pseudobulbar Affect

Search GEO for disease gene expression data for Pseudobulbar Affect.

Pathways for Pseudobulbar Affect

GO Terms for Pseudobulbar Affect

Sources for Pseudobulbar Affect

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....